{"Symbol": "ARVN", "AssetType": "Common Stock", "Name": "Arvinas Inc", "Description": "Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins. The company is headquartered in New Haven, Connecticut.", "CIK": "1655759", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "5 SCIENCE PARK, NEW HAVEN, CT, UNITED STATES, 06511", "OfficialSite": "https://www.arvinas.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "855315000", "EBITDA": "-98000000", "PERatio": "None", "PEGRatio": "None", "BookValue": "7.97", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-0.81", "RevenuePerShareTTM": "4.299", "ProfitMargin": "-0.187", "OperatingMarginTTM": "-1.05", "ReturnOnAssetsTTM": "-0.063", "ReturnOnEquityTTM": "-0.102", "RevenueTTM": "312300000", "GrossProfitTTM": "312300000", "DilutedEPSTTM": "-0.81", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.591", "AnalystTargetPrice": "13.5", "AnalystRatingStrongBuy": "2", "AnalystRatingBuy": "8", "AnalystRatingHold": "8", "AnalystRatingSell": "1", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "17.7", "PriceToSalesRatioTTM": "2.739", "PriceToBookRatio": "1.326", "EVToRevenue": "5.69", "EVToEBITDA": "-1.619", "Beta": "1.882", "52WeekHigh": "20.38", "52WeekLow": "5.9", "50DayMovingAverage": "12.5", "200DayMovingAverage": "9.32", "SharesOutstanding": "64224000", "SharesFloat": "56092000", "PercentInsiders": "7.881", "PercentInstitutions": "88.990", "DividendDate": "None", "ExDividendDate": "None"}